Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00324116
Status:
COMPLETED
Last Update Posted:
2010-03-23
First Post:
2006-05-08
Brief Title:
Evaluation Of Safety And Efficacy Of 03 MgEye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Prospective Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 03 MgEye Pegaptanib Sodium Macugen Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration AMD Lesions
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy based on the best-corrected visual acuity using the ETDRS chart of a 03 mgeye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset subfoveal andor juxtafoveal choroidal neovascularization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None